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ABSTRACT
We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-
stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoi-
etic stem cell transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML). The
conditioning regimen consisted of 12 Gy of TBI followed by high-dose cytarabine (3 g/m2) every 12 hours for
4 days in combination with the continuous administration of G-CSF. Stem cell sources included bone marrow
or peripheral blood stem cells (PBSC) from human leukocyte antigen (HLA)-identical siblings (n 5 24), or
bone marrow from HLA serologically matched unrelated donors (n 5 26). Fifty patients (median age, 38 years)
were evaluated. At HSCT, 35 patients were in the first or second complete remission (CR1/2), and 15 patients
were not in remission (n 5 14) or in the third CR (n 5 1). Thirty-six of 50 patients are currently alive, with a
median follow-up period of 5.6 years (range: 1.1-12.1 years). The 5-year estimated overall survival (OS) and dis-
ease-free survival (DFS) rates were 85.5% (95% confidence interval [CI], 73.7%-97.3%) and 82.1% (95% CI,
69.0%-95.2%) in patients with AML in the first or second CR, 46.7% (95% CI, 21.4%-72.0%), and 40.0%
(95% CI, 15.3%-64.7%) in patients with AML in other stages. The 2-year cumulative incidence of treatment-
related mortality (TRM) of all patients was 10.4% (95% CI, 1.8%-18.6%). The only factors affecting the OS
and DFS were disease status at transplant and cytogenetics by multivariate analysis. These results suggest
that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen for
allogeneic HSCT for AML, providing a high DFS and low TRM.
 2008 American Society for Blood and Marrow Transplantation
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Disease recurrence still remains the most impor-
tant factor interfering with the success of allogeneichematopoietic stem cell transplantation (HSCT) for
acute myelogenous leukemia (AML). Disease-free
survival (DFS) of patients with refractory or relapsed651
652 T. Mori et al.AML after allogeneic HSCT has been reported to
range between 21% and 38% [1-11]. Granulocyte col-
ony-stimulating factor (G-CSF) has been shown to
increase the susceptibility of some myelogenous leu-
kemia cells to cytarabine in vitro by recruiting quies-
cent leukemic cells into the cell cycle [12-15]. In this
context, several studies have examined the efficacy of
the combination of G-CSF with cell cycle-specific
chemotherapeutic agents such as cytarabine for refrac-
tory myelogenous malignancies [16,17]. Two recent
randomized trials have shown that addition of G-CSF
to cytarabine-based induction chemotherapy for
newly diagnosed AML patients resulted in a signifi-
cantly higher remission rate or a lower relapse rate
[18,19]. In the setting of HSCT, several studies in-
cluding our previous reports have suggested that G-
CSF-combined conditioning for allogeneic HSCT
for myeloid malignancies contributed to reduced
disease relapse [14,20-23]. To further elucidate the
role of this G-CSF-combined regimen in allogeneic
HSCT for myelogenous malignancies, we assessed
the efficacy of this conditioning with a relatively large
number of patients with de novo AML and a long-
term follow-up period.
PATIENTS AND METHODS
Patients and Donor Characteristics
This study retrospectively evaluated 50 patients
with AML who underwent allogeneic HSCT at Keio
University Hospital between January 1995 and April
2006 after being conditioned with total body irradia-
tion (TBI) and G-CSF-combined high-dose cytara-
bine as described below. Patient and transplant
characteristics are shown in Table 1. The diagnosis
of AML subtypes was based upon the FAB classifica-
tion. Patients with therapy-related AML and AML
transformed from myelodysplastic syndrome were ex-
cluded. Sixteen patients were in the first complete re-
mission (CR1), 19 patients were in the second CR
(CR2), 1 patient was in the third CR, and 14 patients
were not in CR. Cytogenetic analysis of bone marrow
cells was performed by the standard G-banding
method. Three cytogenetic risk categories were de-
fined as follows. The favorable-risk category included
the abnormalities of inv (16)/t(16;16)/del(16q), or
t(15;17) with any additional abnormalities, or t(8;21)
without either having del(9q) or being part of a
complex karyotype. The intermediate-risk category
included 18, 2Y, 16, del(12p), and a normal karyo-
type. The unfavorable-risk category included 25/
del(5q), 27/del(7q), inv(3q), abnormalities of 11q,
20q, or 21q, del(9q), t(6;9), t(9;22), abnormalities of
17p, and a complex karyotype. All other abnormalities
were included in the intermediate-risk category. Only
1 of the 16 patients in CR1 had a favorable-risk cate-
gory. Patients were grouped according to the hemato-poietic cell transplantation (HCT)-comorbidity index
(HCT-ci) assigned at the time of HSCT (scores 0, 1-2,
and $3) [24-26].
Conditioning Regimen
Twelve Gy of TBI was delivered in 6 fractions of 2
Gy each (3 days) or in 4 fractions of 3 Gy each (2 days).
After TBI, cytarabine at a dose of 3 g/m2 was adminis-
tered intravenously over 2 hours every 12 hours for 4
consecutive days. Recombinant humanG-CSF (lenog-
rastim) was given by continuous infusion at a daily dose
of 5 mg/kg, starting 12 hours before the first dose of
cytarabine and continuing until the last dose of cytar-
abine as we have previously reported [20,23]. All pa-
tients received steroid eye drops for the prophylaxis
of keratoconjunctivitis because of cytarabine. No pa-
tients received antithymocyte globulin (ATG) as part
of the conditioning regimen.
Table 1. Patient and Transplant Characteristics (n 5 50)
Median age, years (range) 38 (15-58)
Sex, Male/Female 27/23
FAB subtype
M0 4
M1 11
M2 15
M3 8
M4 6
M5 2
M6 1
Others 3
Risk categories of cytogenetics*
Favorable 15
Intermediate 27
Unfavorable 8
Disease stage at transplant
First CR 16
Second CR 19
Others 15
Primary induction failure 3
Relapse 11
Third CR 1
HCT-Ci score
0 21
1-2 15
$3 14
Stem cell source and donor
Bone marrow/PBSC from related donor 19/5
Bone marrow from unrelated donor 26
CMV serostatus
Recipient 1 or 2 / Donor 1 34
Recipient 1 / Donor 2 8
Recipient 2 / Donor 2 8
GVHD prophylaxis
Cyclosporine plus methotrexate† 22
Tacrolimus plus methotrexate 28
CR indicates complete remission;HCT-ci, hematopoietic cell trans-
plantation-comorbidity index; PBSC, peripheral blood stem
cells; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
*Definition was made as described elsewhere [18]. Details are
described in the text.
†One patient received cyclosporine alone.
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Two days after the completion of cytarabine and
G-CSF administration, patients received bonemarrow
transplantation (BMT) or peripheral blood stem cell
transplantation (PBSCT). The types of donor and hu-
man leukocyte antigen (HLA) compatibility were ei-
ther HLA-A, -B, or -DR identical sibling, or HLA-A,
-B, or -DR serologically matched unrelated donor.
T cell depletion of the graft was not performed in any
of the patients. For the prophylaxis of graft-versus-
host disease (GVHD), patients received cyclosporine
A (CSA; 3mg/kg/day by continuous infusion) or tacro-
limus (0.03 mg/kg/day by continuous infusion) with
short-term methotrexate (15 mg/m2 on day 1, and 10
mg/m2 on days 3 and 6). In cases of unrelated donor
marrow transplantation, recipients received additional
methotrexate (10 mg/m2) on day 11. Each patient was
isolated in a laminar air-flow room and received pro-
phylactic antibiotics and antifungal agents orally. The
administration of lenograstim at a dose of 5 mg/kg
was initiated 1 day after HSCT and continued until
neutrophil recovery was achieved. Regimen-related
toxicities were assessed and graded according to the
National Cancer Institute Common Toxicity Criteria
(version 2.0).
Engraftment and GVHD
The day of myelogenous engfratment was defined
as the first day of 3 consecutive days when the absolute
neutrophil counts exceeded 0.5  109/L. Graft failure
was defined as the lack of myelogenous engraftment in
patients surviving in remission for at least 28 days after
transplantation. Both acute GVHD (aGVHD) and
chronic GVHD (cGVHD) were diagnosed and graded
based on the published criteria [27,28].
Statistical Analysis
OS, DFS, relapse, and nonrelapse mortality
(NRM) curves were calculated by the Kaplan-Meier
method, and comparisons were made using the log-
rank test. Variables analyzed were patient age and
sex, sex match and mismatch between patient and
donor, type of donor, disease status at transplant, risk
categories of cytogenetics, cytomegalovirus (CMV)
serostatus before transplant, HCT-ci scores, GVHD
prophylaxis, development of aGVHD, and any type
of cGVHD. For multivariate analysis, we used the
Cox proportional hazards model with stepwise regres-
sion method. A level of P\ .05 was considered to be
statistically significant.
RESULTS
Regimen-Related Toxicities and Engraftment
Regimen-related toxicities are summarized in
Table 2. The regimens were generally well tolerated.Among the 50 patients, grades 3-4 toxicities were
observed for mucositis (n 5 28), diarrhea (n 5 26),
hepatotoxicity (n 5 6), and conjunctivitis/keratitis
(n5 22). No other grade 3-4 toxicities were observed.
There were 3 regimen-related deaths early after
HSCT; 2 were caused by bacterial infection, and the
other was a primary graft failure. In the remaining 47
patients, myeloid engraftment was achieved at a me-
dian of 19 (range: 13-25) days after transplantation.
aGVHD and cGVHD
The cumulative incidences of grades II-IV and III-
IV aGVHD were 46.2% (95% confidence interval
[CI], 31.9%-60.5%) and 8.2% (95% CI, 0.6%-
15.8%), respectively. No patient developed grade IV
aGVHD. Only 4 recipients of unrelated donor bone
marrow developed grade III aGVHD (15.4%),
whereas none of the recipients of sibling donor bone
marrow or peripheral blood stem cells developed grade
III aGVHD. The cumulative incidences of grades II-
IV aGVHD were 34.8% (95% CI, 15.4%-54.2%)
among HSCT recipients from sibling donors, and
55.9% (95% CI, 36.5%-75.3%) among HSCT recipi-
ents from unrelated donors (P5 .253). Thirty (68.1%)
of 45 evaluable patients developed any grade of
cGVHD (extensive-type 27, limited-type 3). The cu-
mulative incidence of any grade of cGVHD was
82.2% (95% CI, 75.6%-88.8%) among HSCT recipi-
ents from unrelated donors, which was significantly
higher than that among HSCT recipients from sibling
donors (51.5%; 95% CI, 29.9%-73.1%, P\ .05).
Treatment-Related Mortality (TRM), Relapse, and
Survival
The 2-year cumulative incidence of TRM was
10.4% (95% CI, 1.8%-18.6%). It was 8.8% (95% CI,
0%-18.2%) in patients with AML in CR1/2 and
14.4% (95% CI, 0%-33.0%) in patients with AML in
other advanced stages; these results are not significantly
different (P 5 .526; Figure 1A). The causes of TRM
were bacterial infection (n 5 2), fungal infection (n 5
1), aGVHDofgrade III (n51), andprimarygraft failure
(n 5 1). Eleven patients relapsed at 1.3-68.1 months
(median 5.9 months) after transplantation. The 5-year
cumulative incidences of relapse were 15.6% (95% CI,
Table 2. Regimen-Related Toxicities (n 5 50)
Grades*
0 1 2 3 4
Stomatitis 1 4 17 28 0
Diarrhea 0 7 17 26 0
Hepatotoxicity 8 20 16 5 1
Conjunctivitis/Keratit 18 5 5 22 —
*Grades were evaluated accoding to the National Cancer Institute
Common Toxicity Criteria (ver. 2.0).
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Figure 1. Kaplan-Meier estimates of (A) TRM, (B) relapse rate, (C) OS rate, and (D) DFS rate. The 1 indicates a censored patient.9.0%-30.3%) in patients with AML in CR1/2 and
51.8% (95% CI, 24.8%-78.8%) in patients with AML
in other advanced stages (P 5 .001, Figure 1B). The
site of relapse was exclusively the bone marrow.
The follow-up period of the 36 patients who were
alive at the date of analysis ranged from1.1 to 12.1 years,
with amedian of 5.6 years.The 5-year estimatedOSwas
85.5% (95% CI, 73.7%-97.3%) and 46.7% (95% CI,
21.4%-72.0%) in patients with AML in CR1/2 and
in other advanced stages (P 5 .003, Figure 1C). The
5-year estimated DFS rates were 82.1% (95% CI,
69.0%-95.2%) and 40.0% (95% CI, 15.3%-64.7%) in
patients with AML in CR1/2 and in other advanced
stages (P5 .001, Figure 1D). DFS was not significantly
differentbetweenpatients inCR1 (74.0%,95%CI52.0-
96.0%;n5 16) andCR2 (88.4%,95%CI73.2%-100%;
n5 19, P5 .115). The 34 patients who are disease-free
and alive are all in good condition, and have an Eastern
Cooperative Oncology Group (ECOG) performance
status of 0 (n5 32) or 1 (n5 2).
Factors Affecting the Survival after Allogeneic
HSCT
In univariate analysis, disease status at transplant,
risk categories of cytogenetics, aGVHD, and GVHD
prophylaxis significantly affected overall survival
(OS) (Table 3). Disease status at transplant, patient
age at transplant, and aGVHD significantly affected
DFS (Table 3). Other factors, including sex, sex match
or mismatch between patient and donor, type of donor(related or unrelated), donor age, CMV serostatus
before transplant, HCT-ci scores, and any type of
cGVHD did not significantly affect the OS and DFS.
In multivariate analysis, disease status at transplant
and risk categories of cytogenetics significantly af-
fected both OS and DFS (Table 4).
DISCUSSION
Results of this study indicate that TBI and G-CSF
combinedhigh-dose cytarabineoffers promise as a con-
ditioning regimen for patients with de novo AML un-
dergoing allogeneic HSCT by providing a high DFS
rate with a low TRM. In patients with AML in CR1/
2 in our study, the cumulative incidence of disease
relapse was only 15.6%, which is apparently lower
than the reported incidence, as described previously
[1-5]. Furthermore, in patients with refractory or re-
lapsed AML, the cumulative incidence of disease re-
lapse was 51.8%, which was lower than the most of
the reported rates [7-11]. The combination of G-CSF
with chemotherapy is based on the hypothesis that it in-
creases the susceptibility of myelogenous leukemia
cells, thereby contributing to a decrease in the relapse
rate and further increasing the survival rate [12-19]. Al-
thoughnot evaluated in randomized trials in the setting
of HSCT, the results of the previous studies and the
present study suggest that G-CSF-combined condi-
tioning for myelogenous malignancies reduces the re-
lapse rate, and further increases the survival rate
without increasing TRM [14,20-23]. Because the
G-CSF-Combined Conditioning for AML 655previous studies of conditioning regimens consisting of
TBI and high-dose cytarabine without G-CSF in AML
patients is limited, it is also difficult to compare the re-
sults of the present study with those of the previous
studies to evaluate the effect of combination of G-
CSF with conditioning [29,30].
In addition to a low incidence of disease relapse,
a notably low incidence of TRM, 10.4%, contributed
to a high DFS rate in our study. Incidence of TRM
has been reported to range between 17.3% and 49.0%
in patients with AML in CR1 or CR2, and between
40% and 45% in patients with refractory or relapsed
AML. One possible explanation for this lower TRM
rate in our study compared with those reported studies
is the small number of cases of serious regimen-related
toxicities, resulting in the absence of cases of fatal organ
damage. This reduced regimen-related toxicity might
result from the absence of cyclophosphamide in our
conditioning, which is generally included in most of
the myeloablative regimens. Another explanation
for the low incidence of TRM is the use of tacrolimus
for the prophylaxis of GVHD, mainly for HSCT
fromanunrelateddonor,whichmighthave contributed
to the low incidence of severe aGVHD (grade III,
8.2%) without development of grade IV aGVHD.
This latter explanation is supported by the result that
HSCT from an unrelated donor was not a factor nega-
Table 3. Univariate Analysis for Factors Affecting Survival
Overall
Survival (SE)
Disease-Free
Survival (SE)
Disease status at transplant
CR1 or CR2 0.86 (0.06) 0.82 (0.07)
Others 0.46 (0.13) 0.40 (0.13)
P-value .003 .001
Sex
Male 0.77 (0.08) 0.73 (0.09)
Female 0.70 (0.10) 0.65 (0.10)
P-value .759 .741
Age at transplant
\40 0.67 (0.09) 0.59 (0.10)
5 or .40 0.82 (0.08) 0.82 (0.08)
P-value .150 .049
Risk categories of cytogenetics*
Favorable and intermediate 0.78 (0.06) 0.73 (0.07)
Unfavorable 0.50 (0.18) 0.38 (0.17)
P-value .015 .056
Grades of acute GVHD
0-I 0.92 (0.06) 0.88 (0.07)
II-IV 0.64 (0.10) 0.58 (0.11)
P-value .032 .047
GVHD prophylaxis
CsA-based 0.86 (0.08) 0.81 (0.09)
Tacrolimus-based 0.68 (0.09) 0.63 (0.09)
P-value .049 .083
SE indicates standard error; CR, complete remission; GVHD, graft-
versus-host disease; CsA, cyclosporine A.
*Definition was made as described elsewhere [18]. Details are
described in the text.tively affecting the survival rate in this study, whereas it
was so in other studies [11,31].
Because the numbers of cases of relapse and TRM
in our study were small, a statistical evaluation of the
factors affecting the relapse rate and TRM was not
performed. Instead, risk factor analysis was performed
for OS and DFS. Several factors, including disease
status at transplant, categories of cytogenetic analysis,
development of grades II-IV aGVHD, and GVHD
prophylaxis, affected OS and/or DFS in a univariate
analysis. However, only disease status at transplant
and categories of cytogenetic analysis were identified
as factors affecting both OS and DFS in a multivariate
analysis, which is consistent with the results of reported
studies [11,32-34]. Although a G-CSF-combined reg-
imen could have some efficacy in reducing the relapse
rate, further improvements are still required for pa-
tients with AML in advanced disease status or with
unfavorable risk categories of cytogenetic analysis.
In conclusion, TBI and G-CSF-combined high-
dose cytarabine might be a promising conditioning reg-
imen for allogeneic HSCT for patients with AML by
providing a high survival rate with a low TRM. Further
studies to evaluate the efficacy of G-CSF-combined
conditioning should be performed in a randomized trial.
Table 4. Multivariate Analysis for Factors Affecting Survival
Hazard
Ratio (95% CI) P-Values
Overall survival
Disease status at transplant
CR1 or CR2 1 .004
Others 5.333 (4.206-6.460)
Risk categories of cytogenetics*
Favorable and intermediate 1 .01
Unfavorable 2.157 (1.575-2.739)
Acute GVHD
0-1 — NS
2-4 —
GVHD prophylaxis
CsA-based — NS
Tacrolimus-based — NS
Disease-free survival
Disease status at transplant
CR1 or CR2 1 .002
Others 5.284 (4.201-6.325)
Risk categories of cytogenetics*
Favorable and intermediate 1 .026
Unfavorable 1.871 (1.318-2.424)
Age at transplant
\40 — NS
. or 5 40 —
Acute GVHD
0-1 — NS
2-4 —
CR indicates complete remission; GVHD, graft-versus-host disease;
CsA, cyclosporine A.
*Definition was made as described elsewhere [18]. Details are
described in the text.
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